Immunome (NASDAQ:IMNM) Receives New Coverage from Analysts at Guggenheim

Guggenheim assumed coverage on shares of Immunome (NASDAQ:IMNM) in a research note published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $35.00 price target on the stock.

IMNM has been the topic of a number of other research reports. Leerink Partnrs restated an outperform rating on shares of Immunome in a research report on Monday, January 29th. Wedbush lifted their target price on Immunome from $27.00 to $33.00 and gave the company an outperform rating in a research report on Monday, April 1st. Finally, SVB Leerink assumed coverage on Immunome in a research report on Monday, January 29th. They issued an outperform rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $32.67.

Immunome Stock Performance

NASDAQ IMNM opened at $18.85 on Monday. The stock’s fifty day moving average is $23.40 and its two-hundred day moving average is $14.71. The firm has a market capitalization of $1.13 billion, a P/E ratio of -3.50 and a beta of 1.66. Immunome has a fifty-two week low of $4.44 and a fifty-two week high of $30.96.

Hedge Funds Weigh In On Immunome

Hedge funds have recently bought and sold shares of the company. Natixis acquired a new position in Immunome during the 4th quarter worth about $25,000. Dorsey Wright & Associates acquired a new position in Immunome during the 3rd quarter worth about $26,000. UBS Group AG raised its position in Immunome by 1,049.9% in the 3rd quarter. UBS Group AG now owns 15,271 shares of the company’s stock valued at $68,000 after purchasing an additional 13,943 shares in the last quarter. Renaissance Technologies LLC raised its position in Immunome by 53.6% in the 2nd quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock valued at $69,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in Immunome in the 1st quarter valued at about $77,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.